Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings will go public soon. The estimated IPO date is May 1, 2026.
IPO Price Range
$16.00 - $18.00
Shares Offered
11,764,706
Deal Size
$200.00M
Chart not available yet
Data will show when the stock starts trading on May 1, 2026.
| Market Cap | 666.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -63.91M |
| Shares Out | 39.21M |
| EPS (ttm) | -1.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About COAG
Hemab Therapeutics is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann... [Read more]
Industry Biotechnology
Sector Healthcare
IPO Date May 1, 2026
Employees 72
Stock Exchange NASDAQ
Ticker Symbol COAG
Website https://www.hemab.com/
News
Hemab Therapeutics Holdings IPO Registration Document (S-1)
Hemab Therapeutics Holdings has filed to go public with an IPO on the NASDAQ
17 days ago - SEC